A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial)

Kevin C. Maki, David G. Orloff(Medpace (United States)), Stephen J. Nicholls(South Australian Health and Medical Research Institute), Richard L. Dunbar(University of Pennsylvania), Eli M. Roth(Sterling Research Group), Danielle Curcio(Idera Pharmaceuticals (United States)), Judith Johnson(Idera Pharmaceuticals (United States)), Douglas Kling(Idera Pharmaceuticals (United States)), Michael H. Davidson(Idera Pharmaceuticals (United States))
Clinical Therapeutics
August 30, 2013
Cited by 105

Abstract


Related Papers

No related papers found

Powered by citation graph analysis